Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OSHA Monitoring NIH External Defibrillator Study, Circulates “Fact Card”

This article was originally published in The Gray Sheet

Executive Summary

The Occupational Safety & Health Administration will weigh results from a NIH study in evaluating the cost-effectiveness of options such as the American Heart Association's proposed public access defibrillation (PAD) program

You may also be interested in...



AED Promotion Should Be Considered OSHA "Priority," OMB Recommends

A survey of small and large private employers could be conducted by the Centers for Disease Control & Prevention's National Institute of Occupational Safety and Health to determine the extent of automatic external defibrillator (AED) use in U.S. workplaces, according to OMB.

Passage Of Defibrillator Bill, Device Studies Could Fuel Debate For OTC Status

Congressional passage of the Cardiac Arrest Survival Act (HR 2498), supported by favorable results of an ongoing NIH sponsored study evaluating public access to automated external defibrillators (AEDs), could pave the way for the eventual over-the-counter availability of the devices.

AED Study To Assess Effects Of Public Access On Heart Attack Survival

Medtronic, Agilent and Survivalink will provide automatic external defibrillators free of charge in a $20 mil., 15-month, multicenter study examining the life saving potential and cost effectiveness of public access to the devices.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel